tradingkey.logo

Nyxoah SA

NYXH
5.020USD
+0.030+0.60%
Close 11/06, 16:00ETQuotes delayed by 15 min
187.93MMarket Cap
LossP/E TTM

Nyxoah SA

5.020
+0.030+0.60%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Nyxoah SA

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nyxoah SA's Score

Industry at a Glance

Industry Ranking
107 / 210
Overall Ranking
258 / 4615
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Strong Buy
Current Rating
13.200
Target Price
+164.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nyxoah SA Highlights

StrengthsRisks
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 46.64% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.17M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.17M.
Overvalued
The company’s latest PE is -2.80, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.21M shares, decreasing 19.87% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.28.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 5.59, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.15M, representing a year-over-year increase of 63.11%, while its net profit experienced a year-over-year increase of 47.36%.

Score

Industry at a Glance

Previous score
5.59
Change
0

Financials

6.66

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.32

Operational Efficiency

2.57

Growth Potential

4.26

Shareholder Returns

7.11

Nyxoah SA's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.75, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.80, which is -100.00% below the recent high of 0.00 and -397.93% above the recent low of -13.93.

Score

Industry at a Glance

Previous score
7.75
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 107/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Nyxoah SA is 13.00, with a high of 15.00 and a low of 12.00.

Score

Industry at a Glance

Previous score
9.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts
Strong Buy
Current Rating
13.200
Target Price
+164.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Nyxoah SA
NYXH
6
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.56, which is lower than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 6.33 and the support level at 4.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.40
Change
0.16

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.133
Sell
RSI(14)
39.282
Neutral
STOCH(KDJ)(9,3,3)
20.064
Neutral
ATR(14)
0.264
High Vlolatility
CCI(14)
-82.618
Neutral
Williams %R
81.667
Oversold
TRIX(12,20)
-0.364
Sell
StochRSI(14)
25.280
Neutral
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
5.070
Sell
MA10
5.138
Sell
MA20
5.548
Sell
MA50
5.420
Sell
MA100
6.389
Sell
MA200
7.389
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Cochlear Limited
5.63M
--
Taub (Robert)
3.98M
+17.27%
Monden (Anneliese)
2.94M
--
Gilde Healthcare Partners B.V.
2.94M
--
ResMed Inc
1.73M
--
Hambrecht (Jürgen)
1.34M
--
Vestal Point Capital, LP
1.11M
-20.57%
BNP Paribas Asset Management Belgium S.A.
742.38K
--
BlackRock Financial Management, Inc.
683.64K
-29.20%
Fidelity Management & Research Company LLC
679.59K
-38.84%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.48, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.82. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.48
Change
0
Beta vs S&P 500 index
0.82
VaR
--
240-Day Maximum Drawdown
+61.29%
240-Day Volatility
+77.29%

Return

Best Daily Return
60 days
+17.17%
120 days
+17.17%
5 years
--
Worst Daily Return
60 days
-8.97%
120 days
-8.97%
5 years
--
Sharpe Ratio
60 days
-1.33
120 days
-0.43
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+61.29%
3 years
+100.00%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.63
3 years
-0.02
5 years
--
Skewness
240 days
-0.02
3 years
+0.71
5 years
--

Volatility

Realised Volatility
240 days
+77.29%
5 years
--
Standardised True Range
240 days
+8.83%
5 years
--
Downside Risk-Adjusted Return
120 days
-76.21%
240 days
-76.21%
Maximum Daily Upside Volatility
60 days
+62.03%
Maximum Daily Downside Volatility
60 days
+56.08%

Liquidity

Average Turnover Rate
60 days
+0.22%
120 days
+0.36%
5 years
--
Turnover Deviation
20 days
+128.05%
60 days
+19.16%
120 days
+92.48%

Peer Comparison

Healthcare Equipment & Supplies
Nyxoah SA
Nyxoah SA
NYXH
6.22 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI